Počet záznamů: 1
Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II
- 1.
SYSNO ASEP 0324996 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II Překlad názvu Potlačení nádorového růstu in vivo mitokanem alfa-tokoferylsukcinátem vyžaduje respirační komplex II Tvůrce(i) Dong, L.F. (AU)
Freeman, R. (AU)
Liu, J. (AU)
Zobalová, Renata (BTO-N) RID
Marin-Hernandez, A. (MX)
Stantic, M. (AU)
Rohlena, Jakub (BTO-N) RID, ORCID
Vališ, Karel (BTO-N)
Rodriguez-Enriquez, S. (MX)
Butcher, B. (AU)
Goodwin, J. (AU)
Brunk, U.T. (SE)
Witting, P. K. (AU)
Moreno-Sanchez, R. (MX)
Scheffler, I.E. (US)
Ralph, S.J. (AU)
Neužil, Jiří (BTO-N) RIDZdroj.dok. Clinical Cancer Research. - : American Association for Cancer Research - ISSN 1078-0432
Roč. 15, č. 5 (2009), s. 1593-1600Poč.str. 8 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova SDHC-mutants ; mitocans ; mitochondrial complex II Vědní obor RIV EB - Genetika a molekulární biologie CEP GA204/08/0811 GA ČR - Grantová agentura ČR IAA500520702 GA AV ČR - Akademie věd CEZ AV0Z50520701 - BTO-N (2007-2013) UT WOS 000263851900013 DOI 10.1158/1078-0432.CCR-08-2439 Anotace Mitochondrial complex II (CII) is emerging as an important target for the mitocan α-tocopheryl succinate (α-TOS) in selectively killing cancer cells. Here, we show that CII also has a major role in the anti-cancer efficacy of the vitamin E analogue in vivo using an animal model of cancer. Wild type, CII-defective (succinate dehydrogenase subunit C, SDHC-mutant) and CII-reconstituted Chinese hamster lung fibroblasts were transformed with H-Ras, and were used to establish xenograft tumours in nude mice. Growth of the SDHC-wild type and SDHC-reconstituted tumours was highly sensitive to α -TOS, whereas the CII-defective tumours were relatively resistant to the drug, assessed by monitoring tumour progression using ultrasound imaging. Since mutations in complex II occur very rarely in human cancers, agents like vitamin E analogues should be effective anti-cancer drugs, and this study provides support for their testing in clinical trials Pracoviště Biotechnologický ústav Kontakt Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Rok sběru 2009
Počet záznamů: 1